Special Delivery $19.043M Market Capitalization Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the speed and efficiency of…
Drug Delivery
Smart Watch, Healthy Heart There was an opportunity for a pun in the headline and I took it. In this week’s sector roundup, we are going to be…
A Genetic Link I recently started watching Netflix’s Archive 81 with my girlfriend. Although we have only watched the first episode, there is a clear focus on mental health. It…
Digital Medicine Society The world is on fire, inflation is through the roof, and there is a literal war occurring in Ukraine. While I believe it is important…
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering biotechnology companies. Whether they…
A Fundamental Problem The opioid crisis has spread like an epidemic across North America. Between January 2016 and March 2019, an estimated 12,800 Canadians died from apparent opioid-related overdoses…
Sector Summary The medical sector is a doozy. From cancer to cardiovascular diseases, areas of high unmet medical need are appearing faster than they can be dealt with. According…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The VIRAL-A20-3 study was performed using Sprague-Dawley rats, with…